Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models

Michelandrea De Cesare, Graziella Pratesi, Silvia Veneroni, Raffaella Bergottini, Franco Zunino

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: Gimatecan, a novel oral lipophilic camptothecin characterized by favorable features at molecular/cellular level and by a promising profile of preclinical activity, is currently in clinical phase I/II. The aim of the study was to additionally investigate the therapeutic potential of the drug in human tumor xenografts growing in different organs as models representative of tumor growth in the clinical setting. Experimental Design: The models include two orthotopic central nervous system tumors, two melanomas growing intracranially, and an ovarian carcinoma growing i.p. In addition, gimatecan was tested against experimental lung metastases of two tumor types (lung and ovarian carcinomas). Gimatecan was delivered by oral gavage according to various schedules (daily or intermittent). The time (in days) mice required to show evident signs of disease was used as end point for drug efficacy. Results: Gimatecan was highly effective in delaying disease manifestations in all tumor systems investigated. In the intracranially growing tumors, a significant time increase (versus control mice) was achieved by the drug administered according to all of the schedules. In addition, almost all treated mice were alive and tumor-free at the end of the experiment in the metastatic models and in the ascitic ovarian tumor. The daily prolonged treatment schedule was the best one. Conclusions: In all tumor systems investigated, including orthotopic tumor growth models and lung metastases, the oral administration of gimatecan showed a therapeutic benefit in terms of survival increase. The good oral availability allowed a prolonged daily treatment regimen, which seems the most promising to exploit the therapeutic potential of the drug.

Original languageEnglish
Pages (from-to)7357-7364
Number of pages8
JournalClinical Cancer Research
Volume10
Issue number21
DOIs
Publication statusPublished - Nov 1 2004

Fingerprint

Camptothecin
Heterografts
Neoplasms
Appointments and Schedules
Pharmaceutical Preparations
Lung
Neoplasm Metastasis
Carcinoma
Therapeutics
ST 1481
Central Nervous System Neoplasms
Growth
Oral Administration
Melanoma
Research Design
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. / De Cesare, Michelandrea; Pratesi, Graziella; Veneroni, Silvia; Bergottini, Raffaella; Zunino, Franco.

In: Clinical Cancer Research, Vol. 10, No. 21, 01.11.2004, p. 7357-7364.

Research output: Contribution to journalArticle

De Cesare, Michelandrea ; Pratesi, Graziella ; Veneroni, Silvia ; Bergottini, Raffaella ; Zunino, Franco. / Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 21. pp. 7357-7364.
@article{0cc1b056238e4647b65cd2c50ecbdcc2,
title = "Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models",
abstract = "Purpose: Gimatecan, a novel oral lipophilic camptothecin characterized by favorable features at molecular/cellular level and by a promising profile of preclinical activity, is currently in clinical phase I/II. The aim of the study was to additionally investigate the therapeutic potential of the drug in human tumor xenografts growing in different organs as models representative of tumor growth in the clinical setting. Experimental Design: The models include two orthotopic central nervous system tumors, two melanomas growing intracranially, and an ovarian carcinoma growing i.p. In addition, gimatecan was tested against experimental lung metastases of two tumor types (lung and ovarian carcinomas). Gimatecan was delivered by oral gavage according to various schedules (daily or intermittent). The time (in days) mice required to show evident signs of disease was used as end point for drug efficacy. Results: Gimatecan was highly effective in delaying disease manifestations in all tumor systems investigated. In the intracranially growing tumors, a significant time increase (versus control mice) was achieved by the drug administered according to all of the schedules. In addition, almost all treated mice were alive and tumor-free at the end of the experiment in the metastatic models and in the ascitic ovarian tumor. The daily prolonged treatment schedule was the best one. Conclusions: In all tumor systems investigated, including orthotopic tumor growth models and lung metastases, the oral administration of gimatecan showed a therapeutic benefit in terms of survival increase. The good oral availability allowed a prolonged daily treatment regimen, which seems the most promising to exploit the therapeutic potential of the drug.",
author = "{De Cesare}, Michelandrea and Graziella Pratesi and Silvia Veneroni and Raffaella Bergottini and Franco Zunino",
year = "2004",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-04-0962",
language = "English",
volume = "10",
pages = "7357--7364",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models

AU - De Cesare, Michelandrea

AU - Pratesi, Graziella

AU - Veneroni, Silvia

AU - Bergottini, Raffaella

AU - Zunino, Franco

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Purpose: Gimatecan, a novel oral lipophilic camptothecin characterized by favorable features at molecular/cellular level and by a promising profile of preclinical activity, is currently in clinical phase I/II. The aim of the study was to additionally investigate the therapeutic potential of the drug in human tumor xenografts growing in different organs as models representative of tumor growth in the clinical setting. Experimental Design: The models include two orthotopic central nervous system tumors, two melanomas growing intracranially, and an ovarian carcinoma growing i.p. In addition, gimatecan was tested against experimental lung metastases of two tumor types (lung and ovarian carcinomas). Gimatecan was delivered by oral gavage according to various schedules (daily or intermittent). The time (in days) mice required to show evident signs of disease was used as end point for drug efficacy. Results: Gimatecan was highly effective in delaying disease manifestations in all tumor systems investigated. In the intracranially growing tumors, a significant time increase (versus control mice) was achieved by the drug administered according to all of the schedules. In addition, almost all treated mice were alive and tumor-free at the end of the experiment in the metastatic models and in the ascitic ovarian tumor. The daily prolonged treatment schedule was the best one. Conclusions: In all tumor systems investigated, including orthotopic tumor growth models and lung metastases, the oral administration of gimatecan showed a therapeutic benefit in terms of survival increase. The good oral availability allowed a prolonged daily treatment regimen, which seems the most promising to exploit the therapeutic potential of the drug.

AB - Purpose: Gimatecan, a novel oral lipophilic camptothecin characterized by favorable features at molecular/cellular level and by a promising profile of preclinical activity, is currently in clinical phase I/II. The aim of the study was to additionally investigate the therapeutic potential of the drug in human tumor xenografts growing in different organs as models representative of tumor growth in the clinical setting. Experimental Design: The models include two orthotopic central nervous system tumors, two melanomas growing intracranially, and an ovarian carcinoma growing i.p. In addition, gimatecan was tested against experimental lung metastases of two tumor types (lung and ovarian carcinomas). Gimatecan was delivered by oral gavage according to various schedules (daily or intermittent). The time (in days) mice required to show evident signs of disease was used as end point for drug efficacy. Results: Gimatecan was highly effective in delaying disease manifestations in all tumor systems investigated. In the intracranially growing tumors, a significant time increase (versus control mice) was achieved by the drug administered according to all of the schedules. In addition, almost all treated mice were alive and tumor-free at the end of the experiment in the metastatic models and in the ascitic ovarian tumor. The daily prolonged treatment schedule was the best one. Conclusions: In all tumor systems investigated, including orthotopic tumor growth models and lung metastases, the oral administration of gimatecan showed a therapeutic benefit in terms of survival increase. The good oral availability allowed a prolonged daily treatment regimen, which seems the most promising to exploit the therapeutic potential of the drug.

UR - http://www.scopus.com/inward/record.url?scp=8444222650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444222650&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0962

DO - 10.1158/1078-0432.CCR-04-0962

M3 - Article

VL - 10

SP - 7357

EP - 7364

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -